Core Viewpoint - The introduction of new insomnia medications, specifically dual orexin receptor antagonists (DORAs), is reducing access restrictions for patients, allowing for easier acquisition through various channels, including e-commerce platforms [1][2]. Group 1: Market Dynamics - Traditional insomnia medications are classified as controlled substances, limiting their availability and leading to potential dependency issues [1]. - The recent commercialization of DORA medications, such as Daridorexant by Xiansheng Pharmaceutical, marks a significant shift in the treatment landscape for insomnia in China [2]. Group 2: Patient Management and Usage Guidelines - Insomnia affects 48.5% of the population aged 18 and above in China, with symptoms including difficulty falling asleep and frequent awakenings [3]. - Experts emphasize the need for proper education on the use of sleep medications, as improper usage can lead to adverse effects on daytime functioning [3][4]. - Clinical assessments are recommended for patients experiencing insomnia symptoms, with specific criteria for diagnosis [4]. Group 3: Clinical Research and Development - Phase III clinical trials for Daridorexant have shown significant improvements, including a reduction in time to fall asleep by 35 minutes and an increase in total sleep time by 1 hour without causing next-day drowsiness [6]. - Ongoing research is necessary to understand the transition from traditional insomnia medications to new DORAs, including dosage adjustments and suitability for special populations [6][7]. - Xiansheng Pharmaceutical plans to invest 30 million yuan over the next three years to expand research on Daridorexant and its applications for various patient demographics [7].